SEARCH

SEARCH BY CITATION

  • 1
    Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T. Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 1989; 43: 63744.
  • 2
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 95767.
  • 3
    Fan S, EI-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 582430.
  • 4
    Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisger DE, Houseman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 80710.
  • 5
    Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995; 34: 91109.
  • 6
    Winograd B, Boven E, Lobbezoo MW, Pinedo HM. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (Review). In Vivo 1987; 1: 113.
  • 7
    Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 1988; 7: 26384.
  • 8
    Fujita M, Fujita F, Taguchi T. Chemosensitivity of human gastrointestinal and breast cancer xenografts in nude mice and predictability to clinical response of anticancer agents. In: SordatB, editor. Immune-deficient animals in experimental medicine. Basel : Karger; 1984. p. 3115.
  • 9
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994; 54: 17026.
  • 10
    Knofel WT, Otto U, Baisch H, Kloppel G. Stability of human renal cell carcinomas during long term serial transplantation into nude mice: histopathology, nuclear grade, mitotic rate, and DNA content in thirty tumors. Cancer Res 1987; 47: 2214.
  • 11
    Fujita M, Hayata S, Taguchi T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. J Surg On-col 1980; 15: 2119.
  • 12
    Sakamoto Y, Fujita M, Fujita F, Tsukamoto F, Koike M, Sugimoto T, Taguchi T. Excellent predictability of human cancer xenografts to clinical response of anticancer agents. Proc Am Assoc Cancer Res 1993; 34: 373.
  • 13
    Fujita F, Fujita M, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T, Taguchi T. Analysis of factors influencing chemosensitivity of human tumor serially transplanted into nude mice. In: WuB-q, ZhengJ, editors. Immune-deficient animals in experimental medicine. Basel : Karger; 1989. p. 28490.
  • 14
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 55662.
  • 15
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 485578.
  • 16
    Wattel E, Preudhomme C, Hecquet B, Varumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 314857.
  • 17
    Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53 AIP1, a potential mediator of p5J-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 84962.
  • 18
    Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 1999; 431: 199209.
  • 19
    Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998; 26: 20513.
  • 20
    O'Connor PM, Jackman L, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Korn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285300.
  • 21
    Alsner J, Hoyer M, Sorensen SB, Overgaard J. Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. Int J Radial Oncol Biol Phys 2001; 49: 51925.